Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Solomon, Benjamin J.
• dc.contributor.author Zhou, Cai Cun
• dc.contributor.author Drilon, Alexander
• dc.contributor.author Park, Keunchil
• dc.contributor.author Wolf, Jurgen
• dc.contributor.author Elamin, Yasir
• dc.contributor.author Davis, Hannah M.
• dc.contributor.author Soldatenkova, Victoria
• dc.contributor.author Sashegyi, Andreas
• dc.contributor.author Lin, Aimee Bence
• dc.contributor.author Lin, Boris K.
• dc.contributor.author Loong, Herbert H. F.
• dc.contributor.author Novello, Silvia
• dc.contributor.author Arriola Aperribay, Edurne
• dc.contributor.author Pérol, Maurice
• dc.contributor.author Goto, Koichi
• dc.contributor.author Santini, Fernando C.
• dc.date.accessioned 2022-02-25T07:02:26Z
• dc.date.available 2022-02-25T07:02:26Z
• dc.date.issued 2021
• dc.description.abstract Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival. Clinical trial registration: NCT04194944 (ClinicalTrials.gov).
• dc.format.mimetype application/pdf
• dc.identifier.citation Solomon BJ, Zhou CC, Drilon A, Park K, Wolf J, Elamin Y, Davis HM, Soldatenkova V, Sashegyi A, Lin AB, Lin BK, F Loong HH, Novello S, Arriola E, Pérol M, Goto K, Santini FC. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol. 2021;17(7):763-73. DOI: 10.2217/fon-2020-0935
• dc.identifier.doi http://dx.doi.org/10.2217/fon-2020-0935
• dc.identifier.issn 1479-6694
• dc.identifier.uri http://hdl.handle.net/10230/52570
• dc.language.iso eng
• dc.publisher Future Medicine Ltd.
• dc.relation.ispartof Future Oncol. 2021;17(7):763-73
• dc.rights This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Phase III trial
• dc.subject.keyword RET fusion-positive
• dc.subject.keyword RET kinase inhibitor
• dc.subject.keyword RET rearrangement
• dc.subject.keyword Non-small-cell lung cancer
• dc.subject.keyword Selpercatinib
• dc.subject.keyword Targeted therapy
• dc.title Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion